Loading patent…
AssigneeChengdu Jinrui Foundation Biotech Co., Ltd.
InventorsHaoyu Ye, Tianmin Zhu, Neng Qiu
Estimating the term…
The present invention provides honokiol crystal forms A, B and C and amorphous form and a preparation method thereof, wherein the preparation method comprises dissolving honokiol in n-heptane and standing at room temperature overnight to obtain the separated crystal as honokiol crystal form A; heating the honokiol crystal form A and cooling to room temperature to obtain a solid as honokiol crystal form B; heating the honokiol crystal form A to the molten state and then standing at quenching temperature to obtain the separated crystal as honokiol crystal form C; and adding the honokiol crystal form A with an antisolvent in DMSO/H2O system, and thus obtaining the oily matter as honokiol amorphous form. The honokiol crystal forms A, B and C and the amorphous form of the present invention have the advantages of good solubility, good stability, low hygroscopicity, long-term storage and/or good reproducibility, and are suitable for drug development.
A honokiol crystal form A, wherein a X-ray powder diffraction pattern of the honokiol crystal form A comprises characteristic peaks at 2theta values of 6.79°±0.2°, 9.10°±0.2°, 13.97°±0.2°, 14.97°±0.2° and 17.54°±0.2° under Cu-Kα radiation.
A honokiol crystal form B, wherein a X-ray powder diffraction pattern of the honokiol crystal form B comprises characteristic peaks at 2theta values of 6.15°±0.2°, 6.76°±0.2°, 8.96°±0.2° and 15.90°±0.2° under Cu-Kα radiation.
A honokiol crystal form C, wherein a X-ray powder diffraction pattern of the honokiol crystal form C comprises characteristic peaks at 2theta values of 14.04°±0.2°, 15.84°±0.2°, 17.42°±0.2° and 19.48°±0.2° under Cu-Kα radiation.
An honokiol amorphous form, wherein the honokiol amorphous form has an X-ray powder diffraction pattern as shown in FIG. 19.
Dependencies are inferred from the claim text.